Immune checkpoint inhibitors (ICI) (i.e., inhibitors of PD-1/PD-L1 and CTLA-4) are a class of immunotherapy that have been highly successful in treating lung cancer and have become an important part of the lung cancer treatment algorithm. The gene discussed is CD274; the disease is lung cancer.